atenolol has been researched along with Cerebrovascular Disorders in 28 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 7.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "In persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%, with 5-year absolute benefit of 30 events per 1000 participants." | 5.07 | Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. ( , 1991) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 3.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "To investigate whether the lower the blood pressure (BP) the better the prognosis for the patient with moderate-to-severe hypertension, an assessment was made of 902 patients who received the beta 1-selective beta-blocker atenolol (median dose 100 mg a day), either alone or with other antihypertensive agents, for up to 10 years (mean 6." | 3.67 | Benefits and potential harm of lowering high blood pressure. ( Cruickshank, JM; Thorp, JM; Zacharias, FJ, 1987) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "If atenolol was contraindicated, 0." | 2.67 | Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. ( Applegate, WB; Camel, GH; Greenlick, MR; Hadley, E; Luhr, J; Moye, L; Perry, HM; Pressel, S; Shekelle, RB; Wittes, J, 1994) |
| "Isolated systolic hypertension has a higher prevalence with age and an associated excess cardiovascular risk." | 2.67 | Conclusions and implications of the systolic hypertension in the elderly program. ( Davis, BR; Hawkins, CM; Moyé, LA; Probstfield, JL, 1993) |
| "The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials." | 2.67 | Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. ( , 1993) |
| "A randomised trial of the treatment of hypertension in 884 patients aged 60 to 79 years at the onset showed a reduction of 18/11 mm Hg in blood pressure over a mean follow up period of 4." | 2.66 | Randomised trial of treatment of hypertension in elderly patients in primary care. ( Coope, J; Warrender, TS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 19 (67.86) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warmack, TS | 1 |
| Estes, MA | 1 |
| Heldenbrand, S | 1 |
| Franks, AM | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 1 |
| Kappelle, LJ | 3 |
| van Latum, JC | 2 |
| van Swieten, JC | 2 |
| Algra, A | 3 |
| Koudstaal, PJ | 2 |
| van Gijn, J | 3 |
| Applegate, WB | 2 |
| Pressel, S | 1 |
| Wittes, J | 2 |
| Luhr, J | 1 |
| Shekelle, RB | 1 |
| Camel, GH | 1 |
| Greenlick, MR | 1 |
| Hadley, E | 1 |
| Moye, L | 1 |
| Perry, HM | 1 |
| Moyé, LA | 1 |
| Davis, BR | 3 |
| Hawkins, CM | 2 |
| Probstfield, JL | 2 |
| Cillessen, JP | 1 |
| Vogt, T | 1 |
| Frost, PH | 1 |
| Burlando, A | 1 |
| Cohen, J | 1 |
| Wilson, A | 1 |
| Brass, LM | 1 |
| Frishman, W | 1 |
| Price, T | 1 |
| Stamler, J | 1 |
| Black, HR | 1 |
| Elliott, WJ | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Grimm, RH | 1 |
| Hansson, L | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Sleight, P | 1 |
| Weber, MA | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Zanchetti, A | 1 |
| Fakouhi, TD | 1 |
| Singer, RB | 1 |
| Pop, GA | 1 |
| Ménard, J | 1 |
| Chatellier, G | 1 |
| Petrovitch, H | 1 |
| Vogt, TM | 1 |
| Berge, KG | 1 |
| Coutard, M | 1 |
| Osborne-Pellegrin, M | 1 |
| Oppenheimer, SM | 1 |
| Cechetto, DF | 1 |
| Cruickshank, JM | 4 |
| Borhani, NO | 1 |
| Curb, JD | 1 |
| Cutler, JA | 1 |
| Furberg, CD | 1 |
| Lakatos, E | 1 |
| Page, LB | 1 |
| Thorp, JM | 2 |
| Zacharias, FJ | 2 |
| Coope, J | 1 |
| Warrender, TS | 1 |
| Barer, DH | 2 |
| Ebrahim, SB | 2 |
| Mitchell, JR | 2 |
| Higgins, TJ | 1 |
| Pennert, K | 1 |
| Zacharias, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108] | 200 participants (Anticipated) | Observational | 2018-02-24 | Recruiting | |||
| Hypertension Prevalence, Treatment Patterns and Outcomes in Long-Term Care Facilities[NCT03046420] | 139 participants (Actual) | Observational | 2017-01-26 | Completed | |||
| Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial[NCT03015311] | 8,000 participants (Anticipated) | Interventional | 2017-01-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for atenolol and Cerebrovascular Disorders
| Article | Year |
|---|---|
Beta-adrenergic antagonists in hypertension: a review of the evidence.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovasc | 2009 |
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Dis | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
19 trials available for atenolol and Cerebrovascular Disorders
| Article | Year |
|---|---|
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female; | 1995 |
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlorthali | 1994 |
Conclusions and implications of the systolic hypertension in the elderly program.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Does cerebral infarction after a previous warning occur in the same vascular territory?
Topics: Aspirin; Atenolol; Basilar Artery; Carotid Arteries; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
Topics: Aged; Atenolol; Blood Pressure; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transien | 1993 |
Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Cerebr | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.
Topics: Aspirin; Atenolol; Cerebrovascular Disorders; Disability Evaluation; Follow-Up Studies; Humans; Isch | 1988 |
Randomised trial of treatment of hypertension in elderly patients in primary care.
Topics: Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Cerebrovascular Disorders; Clinical Trials as T | 1986 |
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation.
Topics: Activities of Daily Living; Aged; Atenolol; Brain; Cerebrovascular Disorders; Clinical Trials as Top | 1988 |
The pragmatic approach to stroke trial design: stroke register, pilot trial, assessment of neurological then functional outcome.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1988 |
7 other studies available for atenolol and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
Stroke in the elderly treated for systolic hypertension (SHEP).
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlor | 1991 |
Rupture of the internal elastic lamina and vascular fragility in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arteries; Atenolol; Blood Pressure; Capillary Fragility; Captopril; Cerebrovascular Disorde | 1991 |
Cardiac chronotropic organization of the rat insular cortex.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Atropine; Cerebral Cortex; Cerebrovascular Disorders; Elect | 1990 |
Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
Topics: Atenolol; Blood Pressure; Cerebrovascular Disorders; Electrocardiography; Female; Humans; Hypertensi | 1990 |
Benefits and potential harm of lowering high blood pressure.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1987 |
The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cardiomyopathy, Hypertrophic; Cerebrovascular Dis | 1987 |